TNF Pharmaceuticals (NASDAQ:TNFA) versus Ricoh (OTCMKTS:RICOY) Head-To-Head Review

Ricoh (OTCMKTS:RICOY) and TNF Pharmaceuticals (NASDAQ:TNFA) are both technology companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Ricoh and TNF Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ricoh	3.10%	6.98%	3.24%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Valuation and Earnings

This table compares Ricoh and TNF Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ricoh	$17.33 billion	0.31	$367.42 million	$0.94	10.16
TNF Pharmaceuticals	N/A	N/A	-$23.36 million	($231.00)	-0.01

Ricoh has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than Ricoh, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Ricoh and TNF Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ricoh	0	0	0	0	0.00
TNF Pharmaceuticals	1	0	0	0	1.00

Volatility and Risk

Ricoh has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500.

Institutional and Insider Ownership

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 0.4% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ricoh beats TNF Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Ricoh

Ricoh Company, Ltd. provides office, commercial printing, and related solutions worldwide. It operates through Digital services, Digital Products, Graphic Communications, Industrial Solutions, and Other segments. The company sells multifunctional printers (MFPs), laser printers, digital duplicators, wide format printers, facsimile machines, scanners, personal computers, servers, network equipment, related parts and supplies, services, and support and service and solutions related to documents. It also offers production and OEM services for MFPs, laser printers, digital duplicators, wide format printers, facsimile machine, scanners, network equipment, and related parts and supplies. In addition, the company produces and sells cut sheet printers, continuous feed printers, inkjet heads, imaging systems, industrial printers, related parts and supplies, services, and support and software. Further, it produces and sells thermal paper and media products, industrial optical components/modules, and electronic components and precision mechanical components, as well as offers digital cameras, 360°cameras, and environment and healthcare products. The company was formerly known as Riken Optical Co., Ltd. and changed its name to Ricoh Company, Ltd. in 1963. Ricoh Company, Ltd. was incorporated in 1936 and is headquartered in Tokyo, Japan.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.